Legend Biotech

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

News

Carvykti, Abecma move earlier in multiple myeloma treatment

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one pri

News

CAR-T earlier use backing in multiple myeloma

CAR-Ts set to move earlier in multiple myeloma therapy

FDA advisors have said that two BCMA-targeted CAR-T therapies can be used earlier in the treatment pathway for multiple myeloma, setting up FDA approvals for use in a broa

News

Abecma delay gives Carvykti a chance to catch up

Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy f

News

Trial sets up earlier use of J&J's Carvykti in myeloma

One of Johnson & Johnson's top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti.

News

Janssen, Legend CAR-T therapy CARVYKTI gets FDA nod

The US Food and Drug Administration (FDA) has approved a new cell-based therapy for blood cancer, developed by Janssen and China's Legend Biotech to treat multiple myeloma.

ASCO26: In vivo CAR-Ts in the spotlight

Carvykti, Abecma move earlier in multiple myeloma treatment

CAR-Ts set to move earlier in multiple myeloma therapy

Abecma delay gives Carvykti a chance to catch up

Trial sets up earlier use of J&J's Carvykti in myeloma

Janssen, Legend CAR-T therapy CARVYKTI gets FDA nod

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Legend Biotech

Editor's Picks